Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elisabeth GE de Vries"'
Autor:
Elisabeth GE de Vries, Marjolijn N Lub-de Hooge, Sjoukje F Oosting, Pim P van de Donk, Daan G Knapen, Anthonie J van der Wekken, Adrienne H Brouwers, Derk-Jan A de Groot
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology. These monoclonal antibody-based therapies allow the immune system to recognize and eliminate malignant cells. This has resulted in improved survival of patient
Externí odkaz:
https://doaj.org/article/1c4117e2a0ec420c864e6d697316ea5b
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/21aa504d21734cc9afb031296a1f396f
Autor:
Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Probody® therapeutics are antibody prodrugs designed to be activated by tumor-associated proteases. This conditional activation restricts antibody binding to the tumor microenvironment, thereby minimizing ‘off-tumor’ toxicity. Here, w
Externí odkaz:
https://doaj.org/article/bede17be06fa40b884678abba71d0fbe
Autor:
Stijn JH Waaijer, Danique Giesen, Takahiro Ishiguro, Yuji Sano, Naofumi Sugaya, Carolina P Schröder, Elisabeth GE de Vries, Marjolijn N Lub-de Hooge
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundBispecific antibodies redirecting T cells to the tumor obtain increasing interest as potential cancer immunotherapy. ERY974, a full-length bispecific antibody targeting CD3ε on T cells and glypican 3 (GPC3) on tumors, has been in clinical
Externí odkaz:
https://doaj.org/article/a1a53ef092b3422ca67f8a18cecc7414
Autor:
Pim P van de Donk, Sjoukje F Oosting, Daan G Knapen, Anthonie J van der Wekken, Adrienne H Brouwers, Marjolijn N Lub-de Hooge, Derk-Jan A de Groot, Elisabeth GE de Vries
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004949
The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology. These monoclonal antibody-based therapies allow the immune system to recognize and eliminate malignant cells. This has resulted in improved survival of patient
Autor:
Elisabeth GE de Vries
Publikováno v:
Nuclear Medicine and Biology. :S1
Autor:
Jan J Koornstra, Jan H Kleibeuker, Caroline MM van Geelen, Fleur EM Rijcken, Harry Hollema, Elisabeth GE de Vries, Steven de Jong
Publikováno v:
Journal of Pathology; Jul2003, Vol. 200 Issue 3, p327-335, 9p
Publikováno v:
Journal of Pathology; Jun2003, Vol. 200 Issue 2, p137-148, 12p